The "Quad God" is also pretty good at backflips. U.S. figure skating star Ilia Malinin-- who dubbed himself "Quad God" for his ability to land the quadruple axel -- made his debut at at the 2026 Milan ...

GPIQ remains a buy for long-term investors, despite recent underperformance versus QYLD in a sideways market. GPIQ's active, growth-focused strategy preserves upside by covering only ~38.5% of its ...

The figure skating team event opens competition at the Milano Cortina 2026 Winter Olympics, bringing together 10 countries in a fast-paced format that awards the first skating medal of the Games.

Ilia Malinin surprisingly took second in the men's short program portion of the figure skating team event on Saturday. Malinin, the overwhelming favorite in the men's singles event, took second on ...

The Trump administration is promoting a new drug program it says will will reduce costs for Americans: TrumpRx. The initiative offers American consumers a method to buy prescription medicines at a ...

A warmer atmosphere has the potential to hold more moisture, which can contribute to heavier precipitation in any season, scientists say. By Sachi Kitajima Mulkey Climate misinformation tends to ...

The Boulet administration has announced a reorganization of the public works departments of Lafayette Consolidated Government. There now is a Capital Improvements Department, which will be headed by ...

Charlie Garcia is the founder of R360, a global community of individuals and families with a net worth of $100 million or more. He is editor-in-chief of the Night Owl, R360’s exclusive publication ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Work is no longer contained within a single job structure. Execution increasingly moves ...

2026 will bring several lunar events that backyard astronomers will want to stay awake for. The first full moon of the year will take place on Saturday, Jan. 3, and is known as the Wolf Moon, ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...